Article Text
Statistics from Altmetric.com
Footnotes
-
Contributors MS, individual contribution to the manuscript—Drafting, revising, conducting and reporting the manuscript's content, including medical writing of content. AD, individual contribution to the manuscript—Drafting, revising and planning the manuscript's content, including medical writing of content. BP, individual contribution to the manuscript—Drafting and reporting the manuscript's content. SAF, individual contribution to the manuscript—Revising the manuscript's content, including medical writing of content. DB-G, individual contribution to the manuscript—Conducting and revising the manuscript's content, including medical writing of content. MS and AD, are responsible for the overall content as guarantors.
-
Funding None.
-
Competing interests None.
-
Provenance and peer review Not commissioned. Externally peer reviewed. This paper was reviewed by Mark Lawden, Leicester, UK.
Read the full text or download the PDF:
Other content recommended for you
- Photodynamic therapy for steroid-associated central serous chorioretinopathy
- Retinal and choroidal changes observed with ‘En face’ enhanced-depth imaging OCT in central serous chorioretinopathy
- Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy
- Optical coherence tomography angiography of flat irregular pigment epithelial detachments in central serous chorioretinopathy
- Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study
- Spironolactone versus observation in the treatment of acute central serous chorioretinopathy
- Discrepancy in current central serous chorioretinopathy classification
- Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy
- Mimics and chameleons of optic neuritis
- Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level